| 33 |
Short DAPT Strategy in the Contemporary PCI Era: Routine or Selective? |
Robert W. Yeh |
Aug. 06. 20 |
| 32 |
Escalation and De-Escalation Strategy for DAPT: Rationale and Evidence |
Dominick J. Angiolillo |
Aug. 06. 20 |
| 31 |
Optimal Choice of Antiplatelet Therapy in Asian Patients |
Kyung Woo Park |
Nov. 29. 16 |
| 30 |
More Than Twelve Months! |
Cheol Whan Lee |
Apr. 20. 15 |
| 29 |
Six Months Enough! |
David Joel Cohen |
Apr. 20. 15 |
| 28 |
Tailoring Antiplatelet Therapy Is Still Necessary? |
Ki-Bae Seung |
May. 15. 12 |
| 27 |
What Is the Optimal Duration of DAPT Following DES Treatment? |
David E. Kandzari |
Jul. 22. 09 |
| 26 |
Anti-Platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib |
Roxana Mehran |
Jul. 22. 09 |
| 25 |
Does the Efficacy of Bivalirudin During PCI Depend on Clopidogrel Pretreatment? |
Matthew Price |
Jul. 22. 09 |
| 24 |
STEMI and NSTEMI Pharmacology Confusion: How to Choose and Use Antithrombins (Unfractionated and Low Molecular Weight Heparins, Bivalirudin, Fondaparinux) and Antiplatelet Agents (Aspirin, Clopidogrel, and Prasugrel) |
Gregg W. Stone |
Jul. 22. 09 |
